Bioequivalence Study of Clobetasol Propionate 0.05% Cream Versus Reference in Corticosteroid-Sensitive Dermatosis Using Skin Blanching Bioassay in Healthy Subjects

The primary objective of this study is to evaluate the **bioequivalence** of a new clobetasol propionate 0.05% topical cream compared to DERMOVAL® 0.05% cream. This is assessed using the skin blanching bioassay in healthy subjects. The clinical relevance of this study lies in determining whether the new formulation is therapeutically equivalent to the established product, which is crucial for ensuring effective treatment of **corticosteroid-sensitive dermatosis**. No secondary objectives are provided for this study.

The clinical trial involves participants diagnosed with **corticosteroid-sensitive dermatosis**. The study population includes both male and female subjects, with an age range categorized under code "3", which typically represents adults. The trial does not involve a vulnerable population. The sponsor has not provided information regarding the total number of participants. Selection criteria and lifestyle considerations such as diet, physical activity, or habits have not been specified. The trial population was selected without any specific mention of key inclusion or exclusion criteria.

The clinical trial is designed to evaluate the **bioequivalence** of a new clobetasol propionate 0.05% topical cream compared to DERMOVAL® 0.05% cream in healthy subjects. The study targets individuals with **corticosteroid-sensitive dermatosis** and is structured as a Phase 2 trial. The trial employs a randomized, double-blind, controlled design to ensure the reliability and validity of the results. The estimated recruitment start date is September 15, 2023, with an anticipated end date of April 30, 2024, indicating a total trial duration of approximately seven and a half months.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized to receive either the investigational product or the comparator. Throughout the trial, follow-up visits will be conducted to monitor safety, efficacy, and adherence to the treatment protocol. The end-of-study visit will conclude the participant's involvement, during which final assessments will be performed to gather comprehensive data on the primary and secondary endpoints.

The expected length of participant involvement is contingent upon the trial's schedule and individual adherence to the protocol. Conditions that may lead to early termination from the study include non-compliance with the study protocol, adverse events that compromise participant safety, or withdrawal of consent. The trial's design and procedures are meticulously crafted to ensure the collection of robust data while maintaining participant safety and scientific integrity.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements is not possible with the given data.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also absent from the provided data. As such, no further details can be included in this description.

The clinical trial is in Phase 2 and is scheduled to have an estimated recruitment start date of September 15, 2023, with an estimated end date of April 30, 2024. The trial's efficacy will be assessed through a structured evaluation process, although specific parameters or endpoints for efficacy assessment are not detailed in the available data. The trial will follow a systematic approach to measure, collect, and analyze efficacy data, adhering to the standards expected in Phase 2 clinical trials. The trial's design will likely include predefined timepoints and validated methods to ensure the reliability and validity of the efficacy assessments. The trial's objective is to gather data that will inform the potential therapeutic benefits and guide further research in subsequent trial phases.